



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

0 268 273  
A2

⑫

## EUROPEAN PATENT APPLICATION

㉑ Application number: 87116984.3

㉑ Int. Cl.4: C07D 211/90, C07D 215/54,  
C07D 401/06, C07D 401/12,  
//C07D221/04, A61K31/445

㉒ Date of filing: 17.11.87

㉓ Priority: 19.11.86 US 932751

㉔ Date of publication of application:  
25.05.88 Bulletin 88/21

㉕ Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

㉖ Applicant: WARNER-LAMBERT COMPANY  
201 Tabor Road  
Morris Plains New Jersey 07950(US)

㉗ Inventor: Anderson, Kevin R.  
1620 Spy Glass Hill NE 15B  
Cedar Rapids Iowa 52402(US)  
Inventor: Sircar, Ila  
3615 Charter Place  
Ann Arbor Michigan 48105(US)

㉘ Representative: Mansmann, Ivo  
c/o Gödecke AG - Patentabteilung Postfach  
569 - Mooswaldallee 1-9  
D-7800 Freiburg(DE)

㉙ Process for the preparation of 2-substituted-1,4-dihydro-pyridines.

㉚ The present invention provides a process for preparing a 2-substituted-1,4-dihydropyridine by providing a regiospecific bromine containing intermediate which is then reacted with a nucleophile to provide a wide range of substituents at the 2-position of 1,4-dihydropyridines. Also the present invention is novel 3-substituted-1,4-dihydropyridines having cardiovascular activity.

## PROCESS FOR THE PREPARATION OF 2-SUBSTITUTED-1,4-DIHYDROPYRIDINES

The present invention is a process for preparing 2-substituted-1,4-dihydropyridines, useful as cardiovascular agents.


U.S. Patent No. 4,567,268 reports a pyridinium bromide perbromide and N-bromo-succinimide as a bromine generator for use in a process to form an internal ester, i.e. lactone, such as tetrahydrofuro (3,4-b) pyridine from a 3,5-diester-1,4-dihydropyridine. However, surprisingly it is now found that a pyridinium bromide perbromide provides a regiospecific brominated intermediate, i.e. having a bromine containing substituent at the 2-position in a 1,4-dihydropyridine. The intermediate, thus, is further reacted with a nucleophile to provide a wide range of 2-substituted-1,4-dihydropyridines in high yields heretofore available only through a complex three part Hantzsch reaction having low yields of products requiring extensive chromatographic separation.

Additionally selected novel 2-substituted-1,4-dihydropyridines having calcium blocking activity are the present invention

The present invention is a process for the preparation of compounds of the formula (I)

15

20



I

wherein Ar is aryl or heteroaryl;


25 R' is hydrogen, lower alkyl or aryl;

R is straight or branched hydrocarbon chain of from two through six carbons;

R1 is CN, CO2R3 wherein R3 is lower alkyl, or is taken together with ---, which is an optional bond to form a fused ring with the dihydropyridine wherein the fused ring is of the formula

30

35



where n is 0 or 1 and Z is

1) A-R2 wherein A is O or S and R2 is

i) alkyl, straight or branched, optionally substituted by


40 (a) hydroxy, (b) alkoxy, (c) NR3R4 wherein R3 and R4 are independently hydrogen or lower alkyl; (d) S(O)nR5 wherein n is zero, one or two and R5 is lower alkyl, aryl, aralkyl wherein ar is aryl and alkyl is an alkylenyl linkage straight or branched having of from one to four carbons or heteroaryl with the proviso that R2 is not alkyl substituted by S(O)nR5 when A is S; or (e) CO2R4 wherein R4 is hydrogen or lower alkyl;

ii) aryl;

45 iii) heteroaryl; or


iv)

50



wherein q is one or two, and - - - is an optional bond; R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, alkyl of from one to four carbons, alkenyl of from two to four carbons, or taken together with - - - R<sub>6</sub> and R<sub>7</sub> form

5



10 wherein X is halogen, lower alkyl, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, cyano, lower alkoxy, lower alkylthio, and the like;

- 2) NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or lower alkyl; or
- 3)


15



wherein Y is O, S, CH<sub>2</sub>, CAr wherein Ar is independently aryl, or NR<sub>5</sub> wherein R<sub>5</sub> is independently as 20 defined above;


4)

25



wherein R<sub>5</sub> is independently as defined above; which comprises treating a compound of the formula (II)

30




II

35

wherein Ar, R, R', and R<sub>1</sub> are as defined above; with pyridinium bromide perbromide in a solvent to obtain an intermediate of the formula (III)

40




III

50 wherein Ar, R<sub>1</sub>, R', and R is as defined above; and then reacting the compound of formula III with a compound of the formula HZ wherein Z is as defined above, to obtain the compound of formula I above.

Since the process can be performed as a one pot process the invention is also the preparation of a compound of formula I as defined above which comprises treating a compound of formula II as defined above with pyridinium bromide perbromide followed by treating with the compound of formula HZ to obtain 55 a compound of the formula I.

The present invention is also for novel compounds of the formula (X)

5




X

10 and pharmaceutically acceptable salts thereof; wherein Ar, R' and R are independently as defined above and Z<sub>1</sub> is


1)

15



wherein R<sub>5</sub> is independently as defined above; or  
20 2)

25



30 wherein q, R<sub>6</sub> and R<sub>7</sub> are as defined above.

The novel compounds of formula X are calcium antagonist useful, for example, as cardiovascular agents in a manner analogous to the calcium channel blocker compounds of EP - A - 0206747.

Thus, the present invention is also a pharmaceutical composition for use in treating cardiovascular diseases comprising a cardiovascular effective amount of the compound of formula X as defined above with 35 a pharmaceutically acceptable carrier.

The present invention is also a method of treating cardiovascular disease in mammals, particularly humans, suffering therefrom which comprises administering to such mammals the compound of formula X as defined above.

The compounds of formula X are useful as salts derived from physiologically acceptable acids. The 40 acids may be mineral acids such as hydrochloric acid, sulfuric acid, and the like, or organic acids, such as sulfamate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and the like; giving the hydrochloride, al, "Pharmaceutical Salts" in J. of Pharmaceutical Sciences, Jan., 1977, Vol. 66, No. 1, pp 1-19.

The compound of formula X of the present invention includes stereoisomers due to the presence of at 45 least one asymmetric carbon atom at the four position of the 1,4-dihydropyridine nucleus and can exist as each optical isomer or a racemic mixture. Further, some of the compounds of formula X which have not less than two asymmetric carbon atoms in its molecule may exist as each diastereomer(s) or the mixture thereof. The mixture of the diastereomers can be resolved to each racemic compound by conventional resolution methods such as chromatography or fractional recrystallization and the like and the racemic 50 compound can be resolved into each optical isomer by a conventional method for racemic resolution by or camphor sulfonic acid.

The terms "stereoisomers" and "stereoisomerism" as used throughout this specification and the 55 appended claims are to be given the meaning usually ascribed to them by practitioners of the organic chemical arts, and specifically as defined by Eliel in "Stereochemistry of Carbon Compounds," pp 1-6, McGraw-Hill, New York, 1962.

The salts of the compounds of formula X; possible when a basic nitrogen is present, are prepared in a manner which is in itself known by reacting the compounds obtained according to the processes of the

invention with suitable acids. For example, the appropriate compounds of formula X are dissolved in ethanol, then suitable acids are added to the solution.

Examples of inorganic and organic acids which form physiologically acceptable acid addition salts with the dihydropyridines of the present invention are hydrogen halide acids, such as hydrochloric acid and hydrobromic acid, particularly hydrochloric, phosphoric, sulfuric, nitric, monofunctional and bifunctional carboxylic acids and hydroxycarboxylic acids, such as acetic, maleic, succinic, fumaric, tartaric, citric, salicylic, lactic, and 1,5-naphthalenedicarboxylic and naphthalenedisulphonic acids.

"Lower alkyl" as used herein means a hydrocarbon chain of from one to six carbons, such as methyl, ethyl, propyl, butyl, pentyl or hexyl and isomers thereof.


The term "aryl" as used herein means phenyl, optionally substituted with one or two of lower alkyl, halogen, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, cyano, lower alkoxy, lower thioalkyl and the like.

The term "heteroaryl" as used herein means thieryl, furyl, pyrryl, pyridinyl, quinolyl, isoquinolyl, pyrimidyl, pyradazinyl, quinazolyl, quinoxalyl, benzothienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, pyrazinyl, oxazinyl, thiazinyl, indolizinyl, indolyl, benzofuranyl, benzoxazolyl, benthiazolyl, benztriazolyl, benzoxadiazolyl, cinnobinyl, phthalaxinyl, naphthyridinyl, or benzothiazinyl.

"Halogen" in the present invention means fluorine, chlorine, or bromine.

20

Scheme I



wherein R, R', R<sub>1</sub>, Ar and Z are as defined above.

Generally, the process of the present invention as shown in Scheme I is carried out in a dry inert solvent, such as trichloromethane, dichloromethane, chloroform, or the like. Water or ethanol and the like can be removed from the medium by standard methods. Further, the process is carried out in the presence of pyridine.

Thus, from at least one equivalent to an excess, such as up to two equivalents, of pyridinium bromide perbromide is added to a mixture of a compound of the formula II in a solvent such as chloroform, methylene chloride and the like. The mixture also contains pyridine or triethylamine, preferably pyridine, in an amount preferably from one equivalent to an excess of equivalents. The mixture is maintained at a temperature from approximately -50°C to 20°C preferably -10 to 0°C. The mixture is stirred until flash chromatography over silica gel (10% ethanol/dichloroethane) indicates a formation of compound of the formula III. The compound of formula III may be isolated for further reaction or the compound of formula III

may be further reacted without separation from the reaction mixture.

The compound of formula III is thus, contacted with a compound of the formula HZ by using a reaction mixture and conditions appropriate to the presence of formation of the moiety of the formula Z. For example, a solvent, such as tetrahydrofuran (THF), N,N-dimethylformamide or the like, may be added to the compound of formula III or the mixture containing the formula III. Then, the solution or mixture of formula III is added to the HZ or a compound providing the Z moiety in a solvent such as one or more of tetrahydrofuran or dimethylformamide and the like preferably in the presence of, for example, sodium hydride if appropriate to the formation of the Z moiety. The resulting reaction mixture is prepared at from -20°C to 0°C and then warmed to room temperature. Then it is stirred until appropriate chromatography indicates the formation of the compound of formula I, approximately an hour for most reactions.

Compounds of formula I may be separated including purification from the reaction mixture by conventional means such as extraction, distillation, chromatography, and the like. Further, the compounds of formula I which are stereoisomers having at least one asymmetric carbon or diastereomers having not less than two asymmetric carbon can be resolved to each racemate by conventional means such as chromatography or fractional recrystallization and the like and the racemate can be resolved into each optical isomer by a conventional racemic resolution by fractional recrystallization of a salt of the racemic compound with an optically active acid, e.g. tartaric acid or camphor sulfonic acid.


The starting materials i.e. the compounds of the formula II as defined above for the process of the present invention are readily available, are known or can be prepared by known methods.

For example, the following Scheme II illustrates one such known process for preparing the starting materials.

Scheme II


25

30



35

40




wherein Ar, R', R<sub>1</sub>, and R are as defined above.

Further, it is understood that optionally additional steps to those described for Scheme I may be used to provide derivatives which are previously known compounds. See, for example, EP - A - (0206747), cited above, for methods shown as the final step shown therein, such as, for example, the following Schemes III and IV:

50


55

Scheme III



wherein Ar, R, R', R<sub>1</sub>, and R<sub>5</sub> are as defined above.

#### Scheme IV



The novel compounds of the formula X as defined above possess vasodilatory activity useful for the treatment of congestive heart failure, coronary heart disease, myocardial ischemia, angina, and hypertension.

5 It is reasonable to believe the compounds of formula X inhibit nitrendipine in an assay as described in EP - A - 0206747 which is incorporated by reference above.

Accordingly, the present invention includes a method for treating mammals, including humans, suffering from the diseases noted above by administering to such mammals a corresponding pharmaceutical composition containing a compound of the formula X as defined above in appropriate unit dosage form. A physician or veterinarian of ordinary skill readily determines a subject exhibiting symptoms of the diseases.

10 The routes of administration and the dosage forms therefor are from among those conventional to the pharmaceutical art. Regardless of the route of administration selected the invention provides a compound of formula X, in unit dosage form comprising the compound either alone or in admixture with a pharmaceutically acceptable carrier appropriately selected from those known.

An effective but nontoxic quantity of the compound X is employed in treatment. The dosage regimen is selected in accordance with a variety of factors including the type, age, weight, sex, and medical condition of the mammal, the severity of symptoms of the disease being treated, the route of administration and particular compound of formula X employed. An ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount of the compound X to prevent or arrest the progress of the disease condition. In so proceeding, the physician or veterinarian could employ relatively low dosages at first, subsequently increasing the dose until a maximum response is obtained. For convenience, the total daily dosage may be divided and administered in portions during the day if desired.

It is understood that the compositions and methods of treatment of the present invention as described above also include the pharmacologically acceptable acid addition salts of the compounds of formula X.

Such variations within the skill of the art are also within the process of the present invention.

25

## EXAMPLES

30 The following examples further illustrate the invention without limiting it thereto.

### EXAMPLE 1

35 Preparation of 3-pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2[4-pyridinylthio]methyl)-4-[(2-trifluoromethyl)phenyl]-, ethyl ester.

5.2 g of 90% pyridinium bromide perbromide was added in one portion to a solution of 5 g of 3-pyridinecarboxylic acid, 5-cyano-1,4-dihydro-2,6-dimethyl-4-[2-(trifluoromethyl)phenyl]-, ethyl ester and 1.2 ml pyridine in 150 ml of dry ethanol-free  $\text{CHCl}_3$  at -10°C. The mixture was stirred for 45 minutes at 0°C and the bromide (6 g) was obtained by flash chromatography over silica gel (10% EtAc/ $\text{CH}_2\text{Cl}_2$ ). This was dissolved in 30 ml of THF and added dropwise to a suspension of 4-mercaptopyridine, sodium salt [- (prepared from 1.5 g of 4-mercaptopyridine and 0.5 g of 60% NaH in THF/DMF (1:1, 40 ml)] at 0°C and the mixture was warmed to room temperature. After stirring for one hour, the reaction mixture was diluted with water and extracted with  $\text{CH}_2\text{Cl}_2$ . The organic extracts were washed with water, dried, and evaporated. The residue was crystallized from EtAc to give 5.1 g of 3-pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2[4-pyridinylthiomethyl]-4-[(2-trifluoromethyl)phenyl]-, ethyl ester, mp 222-224°C.

40 The following additional compounds are obtained by following the procedure described in Example 1 and selecting the requisite substrate.

50

### EXAMPLE 2

55 3-Quinolinecarboxylic acid, 1,4,5,6,7,8-hexahydro-5-oxo-2-[(phenylthio)methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester, mp 178-180°C is obtained from 3-quinolinecarboxylic acid, 1,4,5,6,7,8-hexahydro-5-oxo-2-methyl-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

## EXAMPLE 3

3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-[[4-(phenylmethyl)-1-piperazinyl]methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

5

## EXAMPLE 4

3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-2-[[4-(2-hydroxy-3-phenoxypropyl)-1-piperazinyl]-methyl]-6-methyl-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

10

Calcd. for  $C_{31}H_{34}F_3N_4O_4$


C, 63.80; H, 5.87; N, 9.60

Found C, 63.16; H, 5.99; N, 9.48

mol ion  $m + 1$  584 (mass spectrum)

15

ir,  $2203\text{ cm}^{-1}$  (CN)  $1700\text{ cm}^{-1}$  ( $CO_2Et$ )  
 $^1H$  NMR ( $CDCl_3$ )  $\delta$ : 8.1 (1H, s, broad NH), 6.9-7.6 (9H, m, aromatics), 5.1 (1H, s,  $C_4H$ ), 4.1-3.8 (7H, m, Hs at a, b, c, d), 2.6-2.8 (10H, m,



20

2.1 (3H, s,  $CH_3$ ) and 1.0 (3H, t,  $CO_2CH_2CH_3$ ).

## 25 EXAMPLE 5

3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-(4-morpholinylmethyl)-4-[2-(trifluoromethyl)-phenyl]-, ethyl ester.

mp 174-175°C.

30 Light yellow solid.

## EXAMPLE 6

35 3-Pyridinecarboxylic acid, 5-cyano-2-[(3,4-dihydro-2-oxo-1(2H)-quinolinyl)methyl]-1,4-dihydro-6-methyl-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

mp 210-211°C.

Dull olive solid.

40

## EXAMPLE 7

36 3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-[(4-phenyl-1H-imidazol-1-yl)methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

45 mp 276-278°C.

White solid.

## EXAMPLE 8

50 37 3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-[(2-methyl-1H-imidazol-1-yl)methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.

mp 226-228°C.

55

## EXAMPLE 9

3-Pyridinecarboxylic acid, (trifluoromethyl)phenyl]-, ethyl ester.  
 5 mp 216-218°C.  
 White solid.

## EXAMPLE 10

10 3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-[(4-pyridinylthio)methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.  
 mp 229-230°C.  
 White solid.

15


## EXAMPLE 11

20 3-Pyridinecarboxylic acid, 5-cyano-1,4-dihydro-6-methyl-2-[(phenylthio)methyl]-4-[2-(trifluoromethyl)phenyl]-, ethyl ester.  
 mp 122-123°C.  
 Pale yellow solid.

## 25 Claims

## 1. A process for the preparation of a compound of the formula (I)

30




35

wherein Ar is aryl or heteroaryl;

R' is hydrogen, lower alkyl, or aryl;

40 R is straight or branched hydrocarbon chain of from two through six carbons;  
 R1 is CN, CO2R3 wherein R3 is hydrogen or lower alkyl, or is taken together with - - -, which is an optional bond to form a fused ring of the formula

45



50

wherein n is 0 or 1 and Z is


1) A-R2 wherein A is O or S and R2 is

i) alkyl, straight or branched, optionally substituted by (a) hydroxy, (b) alkoxy, (c) NR3R4 wherein R3 and R4 are independently hydrogen or lower alkyl; (d) S(O)nR5 wherein n is zero, one or two and R5 is lower alkyl, aryl, aralkyl wherein ar is aryl and alkyl is an alkylene linkage straight or branched having of from one to four carbons, or heteroaryl with the proviso that R2 is not alkyl substituted by S(O)nR5 when A is S; or (e) CO2R4 is hydrogen or lower alkyl;

ii) aryl;

iii) heteroaryl; or  
iv)


5



10

wherein q is one or two, and - - - is an optional bond; R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, alkyl of from one to four carbons, alkenyl of from two to four carbons, or taken together with - - - R<sub>6</sub> and R<sub>7</sub> form

15



20

wherein X is halogen, lower alkyl, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, cyano, lower alkoxy, lower alkylthio, and the like;

2) NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or lower alkyl; or  
3)

25




30

wherein Y is O, S, CH<sub>2</sub>, CHAr wherein Ar is independently aryl, or NR<sub>5</sub> wherein R<sub>5</sub> is independently as defined above;

4)


35



wherein R<sub>5</sub> is independently as defined above.

40 which comprises 1) treating a compound of the formula (II)

45



II


50

wherein Ar, R', R<sub>1</sub>, and R are as defined above; with pyridinium bromide perbromide and then 2) treating the result of 1) with a compound of the formula HZ wherein Z is as defined above; to obtain the compound of formula I.

2. A process of Claim 1 wherein the compound of the step 1) having the formula (III)

55

5



III

10 wherein Ar, R', R<sub>1</sub>, and R are as defined above; is identified or isolated and then treated according to step 2 of Claim 1.

3. A process of Claim 2 wherein the step 1 is in a dry, inert solvent and in the presence of pyridine.

4. A process of Claim 4 wherein the solvent is dry ethanol-free chloroform or methylene chloride.


5. A process of Claim 2 wherein step 2 is in a solvent in the presence of NaH.

15 6. A process of Claim 5 wherein the solvent of step 2 is part tetrahydrofuran and part dimethylformamide.

7. A process of Claim 6 wherein each part is equal.

8. A process of Claim 1 wherein Ar is 2-(trifluoromethyl)phenyl, R is ethyl, R<sub>1</sub> is cyano, and Z is


20



25


or

30



9. A compound of the formula (X)

35



X


40

and pharmaceutically acceptable salts thereof; wherein Ar is aryl or heteroaryl;

45 R' is hydrogen, lower alkyl, or aryl;

R is a straight or branched hydrocarbon chain of from two through six carbons; and Z<sub>1</sub> is


50



wherein R<sub>5</sub> is lower alkyl, aryl, aralkyl, or heteroaryl; or


55

5



wherein q is one or two, and R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, alkyl of from one to four carbons, alkenyl of from two to four carbons, or taken together wherein R<sub>6</sub>, R<sub>7</sub> and - - - form

10




15

wherein X is halogen, lower alkyl, trifluoromethyl, nitro, amino, mono- or di-lower alkyl amino, cyano, lower alkoxy, or lower alkylthio.

10. A compound of the Claim 9 wherein Z<sub>1</sub> is


20



25 wherein R<sub>5</sub> is as defined above.

11. A compound of the Claim 9 wherein Z<sub>1</sub> is

30



35 wherein q, R<sub>6</sub> and R<sub>7</sub> are as defined above.

12. A compound of the Claim 11 and being 5-cyano-2-[(3,4-dihydro-2-oxo-1(2H)quinolinyl)methyl]-1,4-dihydro-6-methyl-4[2-(trifluoromethyl) phenyl]-3-pyridinecarboxylic acid; ethyl ester.


13. A compound of the claim 9 selected from the group consisting of 1,4-dihydro-6-methyl-2-[(4-phenyl-1H-imidazol-1-yl)methyl]-4-[2-(trifluoromethyl) phenyl]-3-pyridinecarboxylic acid; ethyl ester, 5-cyano-1,4-dihydro-6-methyl-2-[(2-methyl-1H-imidazol-1-yl)methyl]-4-[2-(trifluoromethyl) phenyl]-3-pyridinecarboxylic acid; ethyl ester, and 5-cyano-1,4-dihydro-2-(1H-imidazol-1-yl) methyl]-6-methyl-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid; ethyl ester.

Claims for the following Contracting States : GR, ES

45

1. A process for the preparation of a compound of the formula (I)

50



I


55

wherein Ar is aryl or heteroaryl;

R' is hydrogen, lower alkyl, or aryl;

R is straight or branched hydrocarbon chain of from two through six carbons;  
 R<sub>1</sub> is CN, CO<sub>2</sub>R<sub>3</sub> wherein R<sub>3</sub> is hydrogen or lower alkyl, or is taken together with - - -, which is an optional bond to form a fused ring of the formula

5




10

wherein n is 0 or 1 and Z is


- 1) A-R<sub>2</sub> wherein A is O or S and R<sub>2</sub> is
  - i) alkyl, straight or branched, optionally substituted by (a) hydroxy, (b) alkoxy, (c) NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or lower alkyl; (d) S(O)<sub>n</sub>R<sub>5</sub> wherein n is zero, one or two and R<sub>5</sub> is lower alkyl, aryl, aralkyl wherein ar is aryl and alkyl is an alkylene linkage straight or branched having of from one to four carbons, or heteroaryl with the proviso that R<sub>2</sub> is not alkyl substituted by S(O)<sub>n</sub>R<sub>5</sub> when A is S; or (e) CO<sub>2</sub>R<sub>4</sub> is hydrogen or lower alkyl;
  - ii) aryl;
  - iii) heteroaryl; or
  - iv)

25



- 30 wherein q is one or two, and - - - is an optional bond; R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, alkyl of from one to four carbons, alkenyl of from two to four carbons, or taken together with - - - R<sub>6</sub> and R<sub>7</sub> form

35



wherein X is halogen, lower alkyl, trifluoromethyl, nitro, amino, mono- or di-lower alkylamino, cyano, lower alkoxy, lower alkylthio, and the like;


- 40 2) NR<sub>3</sub>R<sub>4</sub> wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or lower alkyl; or
- 3)

45



- 50 4)


wherein Y is O, S, CH<sub>2</sub>, CHAr wherein Ar is independently aryl, or NR<sub>5</sub> wherein R<sub>5</sub> is independently as defined above;



55


wherein R<sub>5</sub> is independently as defined above.

which comprises 1) treating a compound of the formula (II)



10 wherein Ar, R', R<sub>1</sub>, and R are as defined above; with pyridinium bromide perbromide and then 2) treating the result of 1) with a compound of the formula HZ wherein Z is as defined above; to obtain the compound of formula I.

15 2. A process of Claim 1 wherein the compound of the step 1) having the formula (III)



wherein Ar, R', R<sub>1</sub>, and R are as defined above; is identified or isolated and then treated according to step 2 of Claim 1.

25 3. A process of Claim 2 wherein the step 1 is in a dry, inert solvent and in the presence of pyridine.


4. A process of Claim 4 wherein the solvent is dry ethanol-free chloroform or methylene chloride.

5. A process of Claim 2 wherein step 2 is in a solvent in the presence of NaH.


6. A process of Claim 5 wherein the solvent of step 2 is part tetrahydrofuran and part dimethylformamide.

30 7. A process of Claim 6 wherein each part is equal.

8. A process of Claim 1 wherein Ar is 2-(trifluoromethyl)phenyl, R is ethyl, R<sub>1</sub> is cyano, and Z is




40 or



45

9. A process of claim 1 for the preparation of a compound of the formula (X)


50



and of pharmaceutically acceptable salts thereof; wherein Ar is aryl or heteroaryl;  
R' is hydrogen, lower alkyl, or aryl;


R is a straight or branched hydrocarbon chain of from two through six carbons; and Z<sub>1</sub> is

5



wherein R<sub>5</sub> is lower alkyl, aryl, aralkyl, or heteroaryl; or


10



15

wherein q is one or two, and R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, alkyl of from one to four carbons, alkenyl of from two to four carbons, or taken together wherein R<sub>6</sub>, R<sub>7</sub> and - - - form


20



25 wherein X is halogen, lower alkyl, trifluoromethyl, nitro, amino, mono- or di-lower alkyl amino, cyano, lower alkoxy, or lower alkylthio.

10. A process of the claim 9 wherein Z<sub>1</sub> is


30



wherein R<sub>5</sub> is as defined above.

35 11. A process of Claim 9 wherein Z<sub>1</sub> is

40



wherein q, R<sub>6</sub> and R<sub>7</sub> are as defined above.

45 12. A process of Claim 11 for preparing 5-cyano-2-[(3,4-dihydro-2-oxo-1(2H)quinolinyl)methyl]-1,4-dihydro-6-methyl-4[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid; ethyl ester.

13. A process of the claim 9 for preparing a compound selected from the group consisting of 1,4-ethyl ester, 5-cyano-1,4-dihydro-6-methyl-2-[(2-methyl-1H-imidazol-1-yl)methyl]-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid; ethyl ester, and 5-cyano-1,4-dihydro-2-(1H-imidazol-1-yl)methyl]-6-methyl-4-[2-(trifluoromethyl)phenyl]-3-pyridinecarboxylic acid; ethyl ester.

55



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑪ Publication number:

0 268 273

A3

⑫

## EUROPEAN PATENT APPLICATION

⑬ Application number: 87116984.3

⑮ Int. Cl.4: C07D 211/90, C07D 215/54,  
C07D 401/06, C07D 401/12,  
//C07D221/04, A61K31/445

⑭ Date of filing: 17.11.87

⑯ Priority: 19.11.86 US 932751

⑰ Applicant: WARNER-LAMBERT COMPANY  
201 Tabor Road  
Morris Plains New Jersey 07950(US)

⑰ Date of publication of application:  
25.05.88 Bulletin 88/21

⑰ Inventor: Anderson, Kevin R.  
1620 Spy Glass Hill NE 15B  
Cedar Rapids Iowa 52402(US)  
Inventor: Sircar, Ila  
3615 Charter Place  
Ann Arbor Michigan 48105(US)

⑰ Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

⑰ Date of deferred publication of the search report:  
02.11.89 Bulletin 89/44

⑰ Representative: Mansmann, Ivo  
c/o Gödecke AG - Patentabteilung Postfach  
569 - Mooswaldallee 1-9  
D-7800 Freiburg(DE)

⑯ Process for the preparation of 2-substituted-1,4-dihydro-pyridines.

⑯ The present invention provides a process for preparing a 2-substituted-1,4-dihydropyridine by providing a regiospecific bromine containing intermediate which is then reacted with a nucleophile to provide a wide range of substituents at the 2-position of 1,4-dihydropyridines. Also the present invention is novel 3-substituted-1,4-dihydropyridines having cardiovascular activity.

EP 0 268 273 A3



EP 87 11 6984

DOCUMENTS CONSIDERED TO BE RELEVANT															
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)												
P, X	EP-A-0 225 175 (FISONS PLC) * Claim 10a; page 9 *	1	C 07 D 211/90 C 07 D 215/54 C 07 D 401/06 C 07 D 401/12 //												
A, D	US-A-4 567 268 (S.D. YOUNG) * Claim 1; column 4 *	1	C 07 D 221/04 A 61 K 31/445												
TECHNICAL FIELDS SEARCHED (Int. Cl.4)															
C 07 D 211/00 C 07 D 215/00 C 07 D 401/00 A 61 K 31/00															
<p>The present search report has been drawn up for all claims</p> <table border="1"> <tr> <td>Place of search <b>THE HAGUE</b></td> <td>Date of completion of the search <b>03-08-1989</b></td> <td>Examiner <b>CASADO Y MARTIN DE MERCIA</b></td> </tr> <tr> <td colspan="3">CATEGORY OF CITED DOCUMENTS</td> </tr> <tr> <td colspan="3">           X : particularly relevant if taken alone            Y : particularly relevant if combined with another document of the same category            A : technological background            O : non-written disclosure            P : intermediate document         </td> </tr> <tr> <td colspan="3">           T : theory or principle underlying the invention            E : earlier patent document, but published on, or after the filing date            D : document cited in the application            L : document cited for other reasons            &amp; : member of the same patent family, corresponding document         </td> </tr> </table>				Place of search <b>THE HAGUE</b>	Date of completion of the search <b>03-08-1989</b>	Examiner <b>CASADO Y MARTIN DE MERCIA</b>	CATEGORY OF CITED DOCUMENTS			X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document		
Place of search <b>THE HAGUE</b>	Date of completion of the search <b>03-08-1989</b>	Examiner <b>CASADO Y MARTIN DE MERCIA</b>													
CATEGORY OF CITED DOCUMENTS															
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document															
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document															